Physician profile
David Canaday
NPI 1093863102
$23,740.28
in general payments reported to CMS, 2019-2025
7 companies · $148 in 2025
The $148 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,116 · 2020: $1,813 · 2022: $7,197 · 2023: $5,563 · 2024: $3,904 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,904 · Travel and Lodging: $1,233 · Food and Beverage: $478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,904.00 |
| Travel and Lodging | $1,232.72 |
| Food and Beverage | $478.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $23,434.52 | 2019-2024 | |
| Shionogi INC | $147.70 | 2025 | Fetroja |
| Genentech, INC. | $62.52 | 2020 | |
| Janssen Scientific Affairs, LLC | $56.06 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $21.90 | 2022 | |
| Merck Sharp & Dohme LLC | $17.58 | 2023 | Delstrigo, Pifeltro, Dificid |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Canaday listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.